Flash Finance

Yatharth Hospital & Trauma Care Services LimitedYATHARTHCorporate

Healthcare Latest results: Mar 2026 13 quarters of data
Consolidated Standalone
₹992.10
MCap ₹9,559 Cr · P/E 99.9
Yatharth Hospital & Trauma Care Services Limited — Stock analysis & AI research Yatharth Hospital & Trauma Care Services Limited — Multibagger AI analysis Yatharth Hospital & Trauma Care Services Limited — Seasonality — best & worst months Yatharth Hospital & Trauma Care Services Limited — Technical indicators & charts Yatharth Hospital & Trauma Care Services Limited — Technical setup — score, trend, support & resistance Yatharth Hospital & Trauma Care Services Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 High Sales Growth Stocks📋 High Profit Growth Stocks 📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹164 Cr
Sales · Mar 2026
+46.4% YoY
₹39 Cr
Operating Profit · Mar 2026
+22.7% YoY
23.8%
OPM % · Mar 2026
-16.2% YoY
₹24 Cr
Net Profit · Mar 2026
+9.6% YoY
₹2.47
EPS · Mar 2026
-3.1% YoY

📝 Yatharth Hospital & Trauma Care Services Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Yatharth Hospital & Trauma Care Services Limited reported revenue of ₹164 crore for the quarter ended March 2026 (Q4 FY26), up 46.4% from ₹112 crore in the same quarter last year, and up 3.7% sequentially over the December 2025 quarter.

Net profit rose 9.6% year-on-year to ₹24 crore, from ₹22 crore. Earnings per share (EPS) came in at ₹2.47.

Operating profit stood at ₹39 crore — an operating margin (OPM) of 23.8%, compared with 28.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Yatharth Hospital & Trauma Care Services Limited posted revenue of ₹590 crore, a growth of 5.4% over FY25, with a net profit of ₹96 crore (down 2.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹590 crore with a net profit of ₹96 crore.

Valuation snapshot

At the current price of ₹992.10, YATHARTH has a market capitalisation of ₹9,559 crore and a trailing P/E of about 99.9.

Within the Healthcare industry, it is the 4th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 55.80%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 10.94%, public shareholders 26.21% of Yatharth Hospital & Trauma Care Services Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹9,559 Cr
Current Price ?
₹992.1
P/E ?
99.93above ind
Industry P/E ?
34.70
P/B ?
5.90
P/S ?
16.21
P/FCF ?
-455.21
Enterprise Value ?
₹9,595 Cr
EV/EBITDA ?
69.76
PEG ?
7.14
Earnings Yield ?
1.1%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹590 Cr
OPM ?
23.3%
Profit after tax (TTM) ?
₹96 Cr
EPS (TTM) ?
₹9.93
ROCE ?
8.0%
ROE ?
5.9%
ROA ?
4.9%
Growth
Sales — latest qtr ?
₹164 Cr
PAT — latest qtr ?
₹24 Cr
YoY qtr sales growth ?
46.4%
YoY qtr profit growth ?
9.6%
Sales growth (3y) ?
21%
Sales growth (5y) ?
29%
Profit growth (3y) ?
14%
Profit growth (5y) ?
51%
Financial Health
Debt ?
₹36 Cr
Debt to Equity ?
0.02
Interest Coverage ?
20.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
55.80%
Change in promoter holding ?
-5.84%
Pledged percentage ?
N/A
Market
Return 3 months ?
17.5%
Return 6 months ?
31.3%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 97102110102106119218110112130137158164 +46.4% +3.7%
Operating Profit 28293129283355323235273739 +22.7% +6.7%
Other Income 0035533347657 +70.8% +28.0%
Interest 2220002000014 +2514.4% +338.6%
Depreciation 433434165556910 +112.4% +11.1%
Profit Before Tax 22243030293140303137273231 -0.0% -3.4%
Net Profit 15162121262331222227212424 +9.6% +0.4%
EPS 2.342.382.452.463.062.703.592.602.552.812.142.482.47 -3.1% -0.4%
OPM % 28.9% 28.4% 28.2% 28.4% 26.4% 27.7% 25.1% 28.8% 28.4% 26.9% 19.6% 23.1% 23.8% -16.2% +3.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹559 Cr ₹590 Cr ₹590 Cr +5.4%
Operating Profit ₹151 Cr ₹138 Cr ₹138 Cr -9.0%
OPM % 27.04% 23.33% 23.33% -13.7%
NPM % 17.54% 16.22% 16.22% -7.5%
Other Income ₹13 Cr ₹26 Cr ₹26 Cr +95.7%
Depreciation ₹30 Cr ₹30 Cr ₹30 Cr +0.5%
Interest ₹2 Cr ₹5 Cr ₹5 Cr +182.6%
EBIT ₹121 Cr ₹108 Cr ₹108 Cr -11.4%
PBT ₹132 Cr ₹127 Cr ₹127 Cr -3.5%
Tax ₹26 Cr ₹25 Cr ₹25 Cr -4.3%
Net Profit ₹98 Cr ₹96 Cr ₹96 Cr -2.5%
EPS ₹11.44 ₹9.90 ₹9.90 -13.5%
Material Cost ₹86 Cr ₹82 Cr ₹82 Cr -4.2%
Employee Cost ₹84 Cr ₹83 Cr ₹83 Cr -0.9%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 66869696 +0.0%
Reserves 1117511,4291,523 +6.6%
Borrowings 1175736 +414.3%
Other Liabilities 333642286 +581.0%
Total Liabilities 3268781,5751,941 +23.2%
Fixed Assets 121133161393 +144.1%
CWIP 0015318 -88.2%
Investments 4767234534 +128.2%
Other Assets 1596791,026996 -2.9%
Total Assets 3268781,5751,941 +23.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 26168995 +6.7%
Cash from Investing Activity -9-167-298-383 -28.5%
Cash from Financing Activity -6241347215 -38.0%
Net Cash Flow 1189138-73 -152.9%
Free Cash Flow 17-18-116-21 +81.9%
CFO/OP 54%44%78%99% +26.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 95133141127 -9.9%
Inventory Days ———28 —
Days Payable ———154 —
Cash Conversion Cycle 951331411 -99.3%
Working Capital Days 8537355197 -82.4%
ROCE % 37%21%10%8% -20.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 61.64%61.64%55.80%55.80%55.80%55.80% +0.0%
FIIs 4.34%6.51%6.18%5.25%5.62%7.05% +25.4%
DIIs 13.52%8.71%11.02%12.00%10.84%10.94% +0.9%
Public 20.50%23.16%27.01%26.94%27.74%26.21% -5.5%
No. of Shareholders 81,44091,43496,22199,11796,26499,397 +3.3%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Yatharth Hospital & Trauma Care Services Limited's revenue in Q4 FY26?
Yatharth Hospital & Trauma Care Services Limited reported revenue of ₹164 crore for the quarter ended March 2026 (Q4 FY26), up 46.4% from ₹112 crore in the same quarter last year, and up 3.7% sequentially over the December 2025 quarter.
What was Yatharth Hospital & Trauma Care Services Limited's net profit in Q4 FY26?
Net profit rose 9.6% year-on-year to ₹24 crore, from ₹22 crore. Earnings per share (EPS) came in at ₹2.47.
What is YATHARTH's market capitalisation and P/E ratio?
At the current price of ₹992.10, YATHARTH has a market capitalisation of ₹9,559 crore and a trailing P/E of about 99.9.
Who owns Yatharth Hospital & Trauma Care Services Limited? (shareholding pattern)
As of Sep 2026, promoters held 55.80%, foreign institutional investors (FIIs) 7.05%, domestic institutional investors (DIIs) 10.94%, public shareholders 26.21% of Yatharth Hospital & Trauma Care Services Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI